SRRA stock: buy or sell?

SRRA stock price: $0.40 -4.76% At close on January 17th, 2020

Updated on:
January 17th, 2020

1

Sierra Oncology shares plummed -4.76% to $0.40 yesterday. On Monday SRRA rocketed an outstanding 22.45%. On Tuesday SRRA plunged a bloodcurdling -11.36%.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally.

Should I buy SRRA stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, Sierra Oncology stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean SRRA will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Sierra Oncology stock a buy?

Financial institutions and banks post stock ratings everyday. Unfortunately, we couldn't find any rating for SRRA stock for the last month.

SRRA stock analysis

Daily outlook

Sierra Oncology plummed a dreadful -4.76% and closed at $0.40.

Shares of Sierra Oncology plummed a dreadful -4.76% and closed at $0.40. From a daily perspective, SRRA is in a short term uptrend after plotting its last bottom ($0.35, on Jan/6) higher than the previous bottom, and its last top ($0.49, on Monday) also over the previous top. Now trading in between its last bottom and last top SRRA might consolidate in a plain range, waiting to break out over $0.49 or down under $0.35. Since price and SMA100d lines crossed up on January/9, SRRA climbed $0.04 (11.11%).

SRRA stock chart (daily)

Weekly outlook

After sliding a dreadful -5.26% in a week last week, Sierra Oncology closed this week at $0.40 and climbed a great 5.26%.

Sierra Oncology stock just marked a top under its last top. Athought it's not a big concern right now, investors in SRRA should be aware as this could be a warning for future complications. You should be expectant to Sierra Oncology price to not slide under , as this would complicate possible price recovery in the short and mid-term. Since late March 2019, when SRRA stock price broke down the 40-weeks moving avarage line, it slid $-1.47 per share (-78.61%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support.

SRRA stock chart (weekly)

SRRA stock price history

SRRA stock went public on July 16th, 2015 with a price of $28.681. Since then, SRRA stock sliced a -98.60%, with a yearly average of -24.70%.

1: Adjusted price after possible price splits or reverse-splits.

SRRA stock historical price chart

SRRA stock reached 52-week highs on March at $2.01, and all-time highs 2015-07-16 with a price of 33.75.

SRRA stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' SRRA stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not found any price prediction for Sierra Oncology stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

Sierra Oncology let down experts on February when it posted an Earnings per Share (EPS) of $-0.19 when the analysts' forecast was $-0.21.
SRRA earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/an/an/a
2017-Q2-n/an/an/a
2017-Q3-n/an/an/a
2017-Q42018-02-27-0.2-0.2n/a
2018-Q12018-05-10-0.22-0.19n/a
2018-Q22018-08-09-0.16-0.16n/a
2018-Q32018-11-08-0.18-0.21n/a
2018-Q42019-02-28-0.21-0.19n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In , Sierra Oncology annual revenues to million dollars from marked in . , its earnings margin (compared to revenues) to , that is million.

SRRA annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY

Quarterly financial results

Reported quarter income marked $-14.28 million with a profit margin of . Profit margin remained constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Sierra Oncology sales marked a tight movement and stayed constant a nan%. Looking back to recent quarterly results, Sierra Oncology posted 7 positive quarters in a row.
SRRA quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2

Sierra Oncology ownership

When you are planning to invest in a stock, it's worth to overview its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Sierra Oncology, 1.07% of all outstanding shares are owned by its staff.

In case of Sierra Oncology stock, 51.89% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SRRA stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related companies:

SRRACSBRPIRS
Market cap$29.9 M$97.6 M$182.0 M
Total shares74.7 M11.6 M55.0 M
Float shares60.6 M4.9 M41.5 M
  - Institutional holdings (%)51.9%50.6%63.3%
  - Insider holdings (%)1.1%21.2%0.2%
Shares in short selling0.0%0.0%0.0%

SRRA summary

Friday, January 17th, 2020
Open$0.42
Close$0.40
Day range$0.40 - $0.43
Previous close$0.42
Session gain-4.76%
Average true range$0.05
50d mov avg$0.35
100d mov avg$0.36
200d mov avg$0.64
Daily patternlt06a
Weekly pattern lt01a

Sierra Oncology performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Sierra Oncology, the comparison is made against Champions Oncology and Pieris Pharmaceuticals.
Stock3m6m12m
SRRASierra Oncology17.65%-27.27%-72.41%
CSBRChampions Oncolog...37.93%9.38%-15.92%
PIRSPieris Pharmaceut...5.08%-27.73%24.91%

Sierra Oncology competitors

Choosing a list of competitors for Sierra Oncology it's tough. We selected 2 public companies that are related to and can be considered as competitors of Sierra Oncology: